Zobrazeno 1 - 10
of 125
pro vyhledávání: ''
Publikováno v:
Schizophrenia Bulletin. 48:447-456
Sleep and circadian rhythm dysfunction is prevalent in schizophrenia, is associated with distress and poorer clinical status, yet remains an under-recognized therapeutic target. The development of new therapies requires the identification of the prim
Autor:
Paola Dazzan, Carmine M. Pariante, John Lally, Tushar Das, Robin M. Murray, Marta Di Forti, Anthony S. David, Tiago Reis Marques, Lena Palaniyappan, Valeria Mondelli, Olesya Ajnakina
Publikováno v:
Schizophrenia Bulletin
Brain and Mind Institute Researchers' Publications
Brain and Mind Institute Researchers' Publications
Treatment resistance (TR) in patients with first-episode psychosis (FEP) is a major cause of disability and functional impairment, yet mechanisms underlying this severe disorder are poorly understood. As one view is that TR has neurodevelopmental roo
Publikováno v:
Schizophrenia Bulletin
Objective The objective of our study was to investigate the comparative effectiveness of antipsychotics for the risk of attempted or completed suicide among all patients with schizophrenia in Finland and Sweden. Methods Two nationwide register-based
Autor:
Detlev Boison, Robert E. McCullumsmith, Ryan C Devore Homan, Cassidy Lynn Moody, Adam J. Funk, Sinead M. O’Donovan, Emily Devine
Publikováno v:
Schizophr Bull
The adenosine hypothesis of schizophrenia posits that reduced availability of the neuromodulator adenosine contributes to dysregulation of dopamine and glutamate transmission and the symptoms associated with schizophrenia. It has been proposed that i
Autor:
Zhening Liu, Guangming Lu, Mingli Li, Xiaohong Ma, Jijun Wang, Wei Cheng, Lena Palaniyappan, Tao Li, Wei Deng, Jianfeng Feng, Wanjun Guo, Qiang Wang, Zhaowen Liu, Jie Zhang, Lin Wan, Xiaojing Li, Kai Zhang, Liansheng Zhao, Timothy J. Crow, Liang Ma
Publikováno v:
Brain and Mind Institute Researchers' Publications
Schizophrenia is genetic in origin and associated with a fecundity disadvantage. The deficits in schizophrenia have been attributed to variation related to the human capacity for language or brain laterality. How sex influences the relative connectiv
Autor:
Lieuwe de Haan, Jentien M Vermeulen, Arjen L. Sutterland, Marita van de Kerkhof, Christoph U. Correll, Geeske van Rooijen
Publikováno v:
Schizophrenia bulletin, 45(2), 315-329. Oxford University Press
Introduction Patients with schizophrenia have an elevated mortality risk compared to the general population, with cardiovascular-related deaths being the leading cause. The role of clozapine use in the long-term mortality risk is unclear. While cloza
Publikováno v:
Schizophrenia Bulletin
Very little is known about the comparative long-term effectiveness of novel antipsychotics in relapse prevention, especially in first-episode schizophrenia. Nationwide data from Finnish health care registers were gathered prospectively for all person
Autor:
Chi-Shin Wu, Shi-Kai Liu, Hui Ju Tsai, Yi-Ling Chien, Hai-Ti Lin, Ming H. Hsieh, I-Ming Chen, Shih-Cheng Liao
Publikováno v:
Schizophrenia Bulletin. 44:798-806
Objectives Despite the decline in the use of electroconvulsive therapy (ECT) in patients with schizophrenia, ECT augmentation is still recommended for those with poor response to standard pharmacological intervention. However, the effectiveness of au
Publikováno v:
Rohde, C, Polcwiartek, C, Asztalos, M & Nielsen, J 2018, ' Effectiveness of Prescription-Based CNS Stimulants on Hospitalization in Patients With Schizophrenia : A Nation-Wide Register Study ', Schizophrenia Bulletin, vol. 44, no. 1, pp. 93-100 . https://doi.org/10.1093/schbul/sbx043
Objective: Negative symptoms and cognitive deficits are main features of schizophrenia but with limited treatment options. Earlier studies have suggested that central nervous system (CNS) stimulants have a small effect on these domains, but with inco
Autor:
James H. MacCabe, Christiane Gasse, Esben Agerbo, Sandra Meier, Henriette Thisted Horsdal, Theresa Wimberley
Publikováno v:
Wimberley, T, Gasse, C, Meier, S M, Agerbo, E, Maccabe, J H & Horsdal, H T 2017, ' Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia ', Schizophrenia Bulletin, vol. 43, no. 5, pp. 1064-1069 . https://doi.org/10.1093/schbul/sbx007
Wimberley, T, Gasse, C, Meier, S M, Agerbo, E, MacCabe, J H & Horsdal, H T 2017, ' Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia ', Schizophrenia Bulletin, vol. 43, no. 5, pp. 1064–1069 . https://doi.org/10.1093/schbul/sbx007
Wimberley, T, Gasse, C, Meier, S M, Agerbo, E, MacCabe, J H & Horsdal, H T 2017, ' Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia ', Schizophrenia Bulletin, vol. 43, no. 5, pp. 1064–1069 . https://doi.org/10.1093/schbul/sbx007
Treatment-resistant schizophrenia (TRS) affects around one-third of individuals with schizophrenia. Although a number of sociodemographic and clinical predictors of TRS have been identified, data on the genetic risk of TRS are sparse. We aimed to inv